Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial.

@article{Ready2010ChemoradiotherapyAG,
  title={Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial.},
  author={Neal E. Ready and Pasi Antero J{\"a}nne and Jeffrey A. Bogart and Thomas A. Dipetrillo and Jennifer Garst and Stephen L. Graziano and Lin Gu and Xiaofei Wang and Mark L. Green and Everett E. Vokes},
  journal={Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer},
  year={2010},
  volume={5 9},
  pages={1382-90}
}
INTRODUCTION This study evaluated the addition of gefitinib to sequential or concurrent chemoradiotherapy (CRT) in unresectable stage III non-small cell lung cancer. METHODS Between May 2002 and April 2005, 63 patients were entered before the study closing early. All received two cycles paclitaxel 200 mg/m and carboplatin area under the curve 6 intravenous plus gefitinib 250 mg daily. Poor risk stratum 1 (> or =5% weight loss and/or performance status 2) received radiotherapy 200 cGy for 33… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 47 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 41 references

Similar Papers

Loading similar papers…